Global trends in COVID-19
- PMID: 38074976
- PMCID: PMC8895648
- DOI: 10.1016/j.imj.2021.08.001
Global trends in COVID-19
Abstract
The pandemic COVID-19 is certainly one of the most severe infectious diseases in human history. In the last 2 years, the COVID-19 pandemic has caused over 418.6 million confirmed cases and 5.8 million deaths worldwide. Young people make up the majority of all infected COVID-19 cases, but the mortality rate is relatively lower compared to older age groups. Currently, about 55.04% individuals have been fully vaccinated rapidly approaching to herd immunity globally. The challenge is that new SARS-CoV-2 variants with potential to evade immunity from natural infection or vaccine continue to emerge. Breakthrough infections have occurred in both SARS-CoV-2 naturally infected and vaccinated individuals, but breakthrough infections tended to exhibit mild or asymptomatic symptoms and lower mortality rates. Therefore, immunity from natural infection or vaccination can reduce SARS-CoV-2 pathogenicity, but neither can completely prevent SARS-CoV-2 infection/reinfection. Fortunately, the morbidity and mortality of COVID-19 continue to decline. The 7-day average cumulative case fatality of COVID-19 has decreased from 12.3% on the February 25, 2020, to 0.27% on January 09, 2022, which could be related to a decreased SARS-CoV-2 variant virulence, vaccine immunization, and/or better treatment of patients. In conclusion, elimination of SARS-CoV-2 in the world could be impossible or at least an arduous task with a long way to go. The best strategy to prevent COVID-19 pandemic is to expand inoculation rate of effective vaccines. As the population reaches herd immunity, the mortality rate of COVID-19 may continue to decrease, and COVID-19 could eventually become another common cold.
Keywords: Breakthrough infection; COVID-19; Case fatality rate; Delta variant; Herd immunity; Omicron variant; SARS-CoV-2; Vaccine.
© 2022 The Author(s).
Conflict of interest statement
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Figures






Similar articles
-
Effects of vaccines on clinical characteristics of convalescent adult patients infected with SARS-CoV-2 Omicron variant: A retrospective study.Front Microbiol. 2023 Mar 30;14:1096022. doi: 10.3389/fmicb.2023.1096022. eCollection 2023. Front Microbiol. 2023. PMID: 37065120 Free PMC article.
-
COVID-19 pandemic dynamics in India, the SARS-CoV-2 Delta variant, and implications for vaccination.medRxiv [Preprint]. 2021 Nov 22:2021.06.21.21259268. doi: 10.1101/2021.06.21.21259268. medRxiv. 2021. Update in: J R Soc Interface. 2022 Jun;19(191):20210900. doi: 10.1098/rsif.2021.0900. PMID: 34845460 Free PMC article. Updated. Preprint.
-
Breakthrough SARS-CoV-2 infections and prediction of moderate-to-severe outcomes during rituximab therapy in patients with rheumatic and musculoskeletal diseases in the UK: a single-centre cohort study.Lancet Rheumatol. 2023 Feb;5(2):e88-e98. doi: 10.1016/S2665-9913(23)00004-8. Epub 2023 Jan 10. Lancet Rheumatol. 2023. PMID: 36712951 Free PMC article.
-
Role of previous infection with SARS-CoV-2 in protecting against omicron reinfections and severe complications of COVID-19 compared to pre-omicron variants: a systematic review.BMC Infect Dis. 2023 Jun 26;23(1):432. doi: 10.1186/s12879-023-08328-3. BMC Infect Dis. 2023. PMID: 37365490 Free PMC article.
-
Insights into COVID-19 Vaccine Development Based on Immunogenic Structural Proteins of SARS-CoV-2, Host Immune Responses, and Herd Immunity.Cells. 2021 Oct 29;10(11):2949. doi: 10.3390/cells10112949. Cells. 2021. PMID: 34831172 Free PMC article. Review.
Cited by
-
Exploring the Potential Medicinal Benefits of Ganoderma lucidum: From Metabolic Disorders to Coronavirus Infections.Foods. 2023 Apr 3;12(7):1512. doi: 10.3390/foods12071512. Foods. 2023. PMID: 37048331 Free PMC article. Review.
-
Evaluation of Potential Peptide-Based Inhibitors against SARS-CoV-2 and Variants of Concern.Biomed Res Int. 2023 Oct 13;2023:3892370. doi: 10.1155/2023/3892370. eCollection 2023. Biomed Res Int. 2023. PMID: 37869628 Free PMC article.
-
Recent advances in nutritional metabolism studies on SARS-CoV-2 infection.Infect Med (Beijing). 2025 Jan 15;4(1):100162. doi: 10.1016/j.imj.2025.100162. eCollection 2025 Mar. Infect Med (Beijing). 2025. PMID: 39936106 Free PMC article. Review.
-
Identifying risk factors for COVID-19 cluster infections in schools in the Republic of Korea: a case-control study.Osong Public Health Res Perspect. 2024 Aug;15(4):375-382. doi: 10.24171/j.phrp.2023.0351. Epub 2024 Jul 11. Osong Public Health Res Perspect. 2024. PMID: 38988091 Free PMC article.
-
COVID-19 Variants and Vaccine Development.Viruses. 2024 May 10;16(5):757. doi: 10.3390/v16050757. Viruses. 2024. PMID: 38793638 Free PMC article. Review.
References
-
- Fung T.S., Liu D.X. Human coronavirus: host-pathogen interaction. Annu Rev Microbiol. 2019;73:529–557. - PubMed
-
- Guan Y., Zheng B.J., He Y.Q., et al. Isolation and characterization of viruses related to the SARS coronavirus from animals in southern China. Science. 2003;302:276–278. - PubMed
-
- Zaki A.M., van Boheemen S., Bestebroer T.M., et al. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med. 2012;367:1814–1820. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous